Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H28ClN5O3 |
Molecular Weight | 457.953 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CCCCN2C(=O)CN(\N=C\C3=CC=C(O3)C4=CC=C(Cl)C=C4)C2=O)CC1
InChI
InChIKey=MREBEPTUUMTTIA-PCLIKHOPSA-N
InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3/b25-16+
Azimilide is a class III antiarrhythmic agent that prolongs cardiac repolarisation by blocking both the rapidly and slowly activating components of the delayed rectifier potassium channel. The most important consequence of this is apparent rate-independent activity, so that, unlike other class III antiarrhythmics, azimilide does not lose efficacy at high heart rates. Azimilide has very predictable pharmacokinetics, is predominantly hepatically metabolized, and has no significant drug interactions with digoxin or warfarin. The most common adverse effects reported by patients on azimilide were approximately equal in frequency with those on placebo: headache, asthenia, infection, diarrhea and dizziness. Azimilide is in phase III clinical trials for the treatment both supraventricular and ventricular tachyarrhythmias.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11033107 |
610.0 nM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Azimilide dihydrochloride: a unique class III antiarrhythmic agent. | 1999 May-Jun |
|
Azimilide dihydrochloride: a new class III anti-arrhythmic agent. | 2000 Nov |
|
Effects of azimilide, a new class III antiarrhythmic drug, on reentrant circuits causing ventricular tachycardia and fibrillation in a canine model of myocardial infarction. | 2001 Sep |
|
Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. | 2005 Jul |
|
The metabolic profile of azimilide in man: in vivo and in vitro evaluations. | 2005 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14739716
100 and 125 mg once daily
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C93038
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
||
|
NCI_THESAURUS |
C47793
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C79923
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
C086123
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
9571004
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
74QU6P2934
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL123558
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
274
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
7299
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
m2174
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB05657MIG
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
100000086104
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
AZIMILIDE
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
DB04957
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
DTXSID10869988
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY | |||
|
149908-53-2
Created by
admin on Fri Dec 15 16:15:31 GMT 2023 , Edited by admin on Fri Dec 15 16:15:31 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)